# AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

> **NCT06938503** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Pancreatic Cancer, Adult

## Interventions

- **DRUG:** AG regimen
- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT06938503
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2028-04-25
- **Final completion:** 2028-04-28
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06938503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06938503, "AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06938503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*